Teva shares slide on generic Copaxone fears

TEL AVIV (Reuters) - Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan.

from

• غرد
• مشاركة
• إضافة